Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.
- Citation:
- N Engl J Med
- Year:
- 2024
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 4156
- Children:
- None
- Program:
- OGC
- Primary Committee:
- GI
- Sec. Committees:
- Health Outcomes
- Pharmas:
- Exelixis
- Grants:
- U10CA180821, U10CA180882, UG1CA189856, UG1CA189804, UG1CA232760, UG1CA233180, UG1CA233290, UG1CA233329, UG1CA233331, UG1CA233339, U10CA180820 (ECOG-ACRIN), U10CA180868 (NRG Oncology), U10CA180888 (SWOG);
- Corr. Author:
- Authors:
- Jennifer A Chan Susan Geyer Tyler Zemla Michael V Knopp Spencer Behr Sydney Pulsipher Fang-Shu Ou Amylou C Dueck Jared Acoba Ardaman Shergill Edward M Wolin Thorvardur R Halfdanarson Bhavana Konda Nikolaos A Trikalinos Bernard Tawfik Nitya Raj Shagufta Shaheen Namrata Vijayvergia Arvind Dasari Jonathan R Strosberg Elise C Kohn Matthew H Kulke Eileen M O'Reilly Jeffrey A Meyerhardt
- Networks:
- CA136, FL065, HAWAII, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY016, LAPS-OH007, NEWMEXICO, NY021
- Study
- Alliance-A021602
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: